Testosterone deficiency has a real, measurable cost, to your drive, your mood, your bones, and your heart. The largest cardiovascular safety trial ever conducted on testosterone therapy has now answered the safety question directly. Here is what it found, and how we give this back to you the right way.

Most men who need this treatment hesitate first, because of a warning most of them never saw the full context of. That warning has now been directly tested, at scale, and answered. This guide walks through what deficiency actually costs you, what the evidence says about safety, and what responsible, physician-supervised treatment looks like.

Written by Mike Fortunato, MD

Board Certified Anesthesiologist · Founder, OptimizeMD

optimizemd.health

Inside this guide: what deficiency actually costs you, why TRAVERSE settled the safety question, how monitoring delivers this safely, and what the evidence shows about long-term health.

OPTIMIZE MDoptimizemd.health

01 / THE CASE FOR TREATING IT

What Deficiency Actually Costs You

Before the safety question, there's a more basic one: what happens if this goes untreated? Decades of research, dozens of randomized trials across thousands of men, show a consistent, reproducible pattern of real cost when testosterone stays low, and real benefit when it's restored.

✓ Libido and sexual function. Consistent, well-replicated improvement in desire and activity across multiple large trials.

✓ Mood. Real, meaningful improvement in depressive symptoms in hypogonadal men.

✓ Muscle mass and strength. The single most consistent finding in the entire research base, increased lean mass, decreased fat mass, increased strength.

✓ Bone density. Increased bone strength, most pronounced in the spine.

✓ Physical function. Improved walking ability and prevention of age-related strength loss in frail older men.

✓ Mental clarity. Some men report sharper focus, though the trial evidence here is more modest and mixed than for the other benefits above.

WHY DEFICIENCY COSTS YOU TWICE, NOT ONCE

Testosterone doesn't just drive motivation and desire on its own. The reward circuitry in the brain, the pathways that govern drive, focus, and the pull toward action, run substantially on dopamine, and that circuitry is directly sensitive to testosterone itself.

But testosterone is also the raw material your body uses to build estradiol, through an enzyme called aromatase. That estradiol, in turn, supports mood, bone density, and cardiovascular protection in men, not just women. When testosterone drops, you are not losing one hormone. You are losing the source of two, and the downstream effects show up in your drive, your mood, your bones, and your heart, all at once.

OPTIMIZE MDoptimizemd.health

02 / THE TRIAL THAT SETTLED IT

TRAVERSE: Why The Fear Doesn't Hold Up

For twenty years, testosterone therapy carried a cardiovascular warning built on conflicting, underpowered retrospective data, never on a definitive trial. That changed in July 2023, when TRAVERSE, the largest and most rigorous cardiovascular safety trial ever conducted on testosterone therapy, published its results in the New England Journal of Medicine. This is the trial that actually answers the question.

TRAVERSE enrolled 5,246 men aged 45 to 80, every one already living with cardiovascular disease or a high risk of it, the population most likely to reveal a cardiovascular danger if one existed, then followed them for an average of nearly three years.

PRIMARY CARDIOVASCULAR OUTCOME

Men on testosterone with a cardiac event

7.0%

Men on placebo with a cardiac event

7.3%

Result

Statistically noninferior to placebo

Men who received testosterone were not more likely to have a heart attack, stroke, or cardiovascular death than men who received placebo. This is the direct, head-to-head answer to the exact fear that kept men off treatment for two decades, and it held up consistently across every sensitivity analysis the investigators ran.

The FDA didn't conclude TRT was dangerous in 2015. It concluded the question hadn't been properly answered yet. TRAVERSE is that answer.

A study of this scale is rare and expensive by design, which is exactly why it carries so much weight. It sits alongside decades of smaller trials and real-world data that tell the same consistent story: testosterone therapy, done under supervision, does not carry the cardiac risk it was once feared to.

OPTIMIZE MDoptimizemd.health

03 / HOW WE DELIVER THIS SAFELY

Restoring What's Missing, Done Right

TRAVERSE didn't just clear testosterone of the cardiac fear it carried for a decade. It confirmed that when this therapy is monitored properly, it is both safe and effective. That's not a caveat sitting next to the good news. It's the reason the good news holds up.

ELEVATED HEMATOCRIT IS NOT “THICK BLOOD”

Testosterone stimulates red blood cell production, a well-documented, normal effect called erythrocytosis, not the vague “thick blood” language that circulates online implying danger at any elevation. The body tolerates a real range of hematocrit levels just fine. Populations who live at high altitude adapt to lower oxygen by running meaningfully elevated hematocrit as their normal baseline, and the overwhelming majority do this without incident. It's a well-tolerated physiological adjustment, not a medical emergency waiting to happen.

Early in treatment, testosterone stimulates a real surge in bone marrow activity, which is what drives that initial rise in red blood cells. When dosing starts at the right level and increases at the correct interval for each patient, the body adapts, hemoglobin and hematocrit rise and then settle into a healthy, balanced range on their own. That's exactly why correct titration from the start matters, and why hematocrit is tracked at regular intervals throughout treatment, to confirm that adaptation, not to react to a problem.

Baseline labs, a real cardiovascular risk assessment, and scheduled hematocrit checks aren't obstacles between you and treatment. They're what makes giving back what's missing something you can trust.

OPTIMIZE MDoptimizemd.health

04 / THE LONGEVITY PICTURE

Low Testosterone And Long-Term Health

Across more than a dozen large population studies, low testosterone is consistently linked to a higher risk of death from any cause. This pattern shows up again and again, in different countries, different age groups, and different research teams, which is exactly the kind of consistency that makes a finding credible.

A CONSISTENT PATTERN ACROSS INDEPENDENT COHORTS

Rancho Bernardo Study (11.8yr follow-up)

Low T linked to higher mortality

MrOS Sweden Study (2,600+ men)

Low T and low estradiol both predicted death

European Prospective Study (11,600+ men)

Low T linked to higher all-cause mortality

What happens when low testosterone is treated? Two notable studies followed men over the long term. In men with type 2 diabetes, those treated with testosterone replacement had a 19.2% reduction in mortality compared with those who went untreated. Men with low testosterone who received treatment have also been shown to have lower mortality than those who did not, tracked over years of follow-up.

These are large, long-term observational studies, not the same design as TRAVERSE, and no single trial has yet been built specifically to prove testosterone therapy extends lifespan the way TRAVERSE was built to test cardiac safety. But the overall picture, low testosterone consistently predicting worse outcomes, and treatment consistently associated with better ones, is a pattern that has repeated for over a decade across independent research groups.

Waiting indefinitely for a perfect trial has a cost too. Men live with treatable deficiency in the meantime.

OPTIMIZE MDoptimizemd.health

05 / THE NEXT STEP

Find Out What Is Actually True For You

The research answers the general question: this is a real hormone worth restoring, and TRAVERSE shows it can be done without the cardiac risk it was once feared to carry. It cannot answer the specific one: what is happening in your body, and what a safe, personalized plan looks like for you.

At OptimizeMD, testosterone therapy is never prescribed off a single number or a symptom checklist. Every patient gets a full hormonal and metabolic workup, a physician who reviews it personally, and ongoing monitoring, hematocrit, cardiovascular risk factors, and more, for as long as treatment continues.

WHAT YOUR EVALUATION ACTUALLY INCLUDES

✓ Full hormonal and metabolic labs. A complete picture, not just a single testosterone number.

✓ A one-on-one review with Dr. Fortunato. Your history and cardiovascular risk factors reviewed by a physician directly.

START YOUR EVALUATION TODAY

Personalized Hormone Optimization, Physician Guided

OptimizeMD offers full hormonal evaluation and physician-managed testosterone therapy, with the monitoring the evidence says it deserves.

optimizemd.health · (702) 763-6233 · [email protected]

Educational disclaimer: This content is for general education only and does not establish a physician patient relationship. Individual symptoms and risk factors vary and may have many causes. Always consult a qualified medical professional before starting, stopping, or changing any medication or hormone therapy.

Sources include: Lincoff AM, Bhasin S, et al. N Engl J Med. 2023;389:107–117. Muraleedharan V, et al. Eur J Endocrinol. 2013;169:725–733. Shores MM, et al. J Clin Endocrinol Metab. 2012;97:2050–2058